他克莫司的药物遗传学及其对肾移植受者个体化治疗的意义

IF 1 Q4 PHARMACOLOGY & PHARMACY

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-19 DOI:10.1080/23808993.2020.1776107

M. Francke, B. D. de Winter, L. Elens, N. Lloberas, D. Hesselink

引用次数: 4

摘要

在获得美国食品药品监督管理局和欧洲药品管理局批准25年后，他克莫司仍然是实体器官移植后免疫抑制治疗的基石[1，2]。这种药非常有效。。。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients

Twenty-five years after its approval by the FDA and EMA, tacrolimus remains the cornerstone of immunosuppressive treatment following solid organ transplantation [1,2]. The drug is highly effective ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Precision Medicine and Drug Development PHARMACOLOGY & PHARMACY-

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.